Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA warns Platinum Strategies

This article was originally published in The Tan Sheet

Executive Summary

FDA warns Platinum Strategies that several of its weight-loss products marketed as dietary supplements are unapproved prescription drugs because they include sibutramine - the active pharmaceutical ingredient in the obesity drug Meridia. In a Sept. 23 warning letter, FDA listsPineapple Fat Reducing Slimming Capsule, Tomato Slimming and other products as unapproved new prescription drugs. The agency also notes the firm's Web site has offered other products that contain sibutramine, including Starcaps. Several NFL players alleged Starcaps, made by Balanced Health Products, contained undeclared bumetanide, a diuretic banned by the league (1"The Tan Sheet" Dec. 1, 2008)

You may also be interested in...

GSK's Quick Warning Of Fake Alli Exemplifies Effective Crisis Management

GlaxoSmithKline's quick response to consumer complaints about counterfeit alli for sale on Internet auction sites exemplifies effective crisis management and could even boost the OTC weight-loss brand's reputation, an expert says

Diuretic found in StarCaps

Balanced Health Products voluntarily recalls one lot of the weight-loss supplement, which contained the undeclared diuretic bumetanide, FDA says Nov. 24. Bumetanide can cause serious loss of fluids and electrolytes and elevated uric acid concentrations. The New York City-based firm's president, Nikki Haskell, suspended shipment of StarCaps after National Football League players alleged the product was tainted after they were suspended for testing positive for bumetanide, which may mask steroid use (1"The Tan Sheet" Nov. 3, 2008, In Brief)

The Quality Lowdown: On Redeploying Inspectors, API Suppliers Thanks To Coronavirus

US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts